Want to see SKYE full AI Analyst Report?
SKYE Stock Chart & Stats
$0.65
-$0.02(-3.42%)
At close: 4:00 PM EDT
$0.65
-$0.02(-3.42%)
Day’s Range― - ―
52-Week Range$0.28 - $4.99
Previous CloseN/A
Volume45.97K
Average Volume (3M)115.36K
Market Cap
$12.72M
Enterprise Value$17.63
Total Cash (Recent Filing)$10.06M
Total Debt (Recent Filing)$35.70K
Price to Earnings (P/E)―
Beta3.19
Next Earnings
Nov 05, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding35,421,413
10 Day Avg. Volume125,555
30 Day Avg. Volume115,358
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.48
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.00Price Target Upside2976.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Financing And Development RunwayThe sizable financing package provides multi-year funding for clinical development, reducing near-term dependence on capital markets and allowing the combined company to pursue important milestones without immediately slowing its pipeline.
Expanded Pipeline In High-unmet-need DiseasesAdding a Phase 2 asset and a broader fibrosis platform diversifies Skye beyond its legacy cannabinoid programs. Fast Track status and an unmet clinical need could support development efficiency and future partnering interest.
Low Absolute Debt BurdenMinimal debt limits interest and refinancing obligations compared with heavily leveraged biotech peers. This preserves financial flexibility for research and development, although the benefit is constrained by the company’s need for external funding.
Bears Say
Pre-revenue Model With Widening LossesWithout commercial revenue, Skye remains dependent on financing or future partnering to support operations. Widening losses indicate that development spending is not yet producing an offsetting earnings base, increasing execution risk.
Persistent Cash Burn And Weakened Capital CushionSubstantial recurring cash outflows convert accounting losses into direct funding needs. Negative equity and declining assets reduce resilience, making continued access to equity, partnership or transaction capital strategically important.
Nasdaq Compliance And Dilution RiskListing compliance uncertainty can complicate financing, strategic execution and investor access. The expanded share authorization gives management flexibility to raise capital, but increases potential dilution while equity remains negative.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience, Inc.’s price range in the past 12 months?
Skye Bioscience, Inc. lowest stock price was $0.28 and its highest was $4.99 in the past 12 months.
What is Skye Bioscience, Inc.’s market cap?
Skye Bioscience, Inc.’s market cap is $12.72M.
When is Skye Bioscience, Inc.’s upcoming earnings report date?
Skye Bioscience, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 77 days.
How were Skye Bioscience, Inc.’s earnings last quarter?
Skye Bioscience, Inc. released its earnings results on Aug 14, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.255 by -$0.015.
Is Skye Bioscience, Inc. overvalued?
According to Wall Street analysts Skye Bioscience, Inc.’s price is currently Undervalued.
Does Skye Bioscience, Inc. pay dividends?
Skye Bioscience, Inc. does not currently pay dividends.
What is Skye Bioscience, Inc.’s EPS estimate?
Skye Bioscience, Inc.’s EPS estimate is -0.21.
How many shares outstanding does Skye Bioscience, Inc. have?
Skye Bioscience, Inc. has 35,421,413 shares outstanding.
What happened to Skye Bioscience, Inc.’s price movement after its last earnings report?
Skye Bioscience, Inc. reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.255. Following the earnings report the stock price went down -7.394%.
Which hedge fund is a major shareholder of Skye Bioscience, Inc.?
Currently, no hedge funds are holding shares in SKYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
SKYE Stock 12 Month Forecast
Average Price Target
$20.00
▲(2976.92% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Outlook Therapeutics
―
Bioxcel Therapeutics
―
Inmune Bio
―
Lantern Pharma
―
Ownership Overview
60.61% Insiders
2.67% Mutual Funds
6.38% Other Institutional Investors
28.21% Public Companies and
Individual Investors